From Root to Ritual
Daily science, ritual, and botanical intelligence for hair and scalp health. By Laritelle Organic.
From Root to Ritual
Saw palmetto vs finasteride: the honest numbers, what the 2025 clinical trials show, and when the botanical is enough — and when it isn't.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Saw palmetto is probably the most researched natural supplement for hair loss. It is also one of the most honestly described when you look at what the clinical evidence actually says rather than what the supplement industry claims. Here are the honest numbers. Clinical studies show saw palmetto inhibits about 30 to 40% of 5-alpha reductus activity, the enzyme that converts testosterone into DHT. For comparison, phenasteride inhibits about 70% and doasteride about 98% of that same enzyme. That comparison frames everything. Saw palmetto is the right class of intervention, 5AR inhibition, at a more modest scale. The question is not whether it works, it does, and the clinical evidence is now substantial. The question is whether the level of DHT reduction it produces is enough for your specific situation. What the research shows. Five studies worth knowing, and what each one actually found. 2002 Pilot RCT. The first structured clinical evidence, a randomized, double-blind, placebo-controlled pilot study published in the Journal of Alternative and Complementary Medicine, in 2002 tested oral saw palmetto plus beta cytosterol in 26 men with mild to moderate androgenetic alopecia for five months. 60% of the saw palmetto group showed improvement versus 11% in the placebo group. Small study, but the first placebo-controlled evidence of a meaningful effect size. 2020 Systematic Review, the most comprehensive analysis, a systematic review in skin appendage disorders, analyzed five RCTs and two prospective cohort studies. Across all studies, 60% of users reported improvement in overall hair quality, 27% in total hair count, and 83.3% demonstrated increased hair density on investigator assessment. The investigator assessment figure, 83.3% showing increased density, is the most clinically meaningful number in the Saw Palmetto evidence base. That is a dermatologist looking at the scalp and recording objective improvement, not a patient self-reporting. 2023 RCT, 80 adults, 16 weeks. A randomized placebo-controlled trial in 80 adults found oral saw palmetto at 320 mg, daily reduced hair fall by 29%, and increased density by 5.17% over 16 weeks. This is a modest but statistically significant density improvement at a specific dose in a well-designed trial. The kind of number you can give a patient who wants to know what to expect. 2025 RCT plus 2026 180-day extension, the most recent evidence. A 2025 90-day randomized controlled trial using a standardized serenoa repens extract showed significant improvements in hair density and quality versus placebo. A 180-day extension, published in 2026, showed continued improvement, with effects strengthening from 90 to 180 days and no adverse events reported. This is the freshest clinical evidence, and it confirms a direction that has been consistent across two decades of trials. Saw Paul Meadow produces meaningful, dose-dependent hair density improvement when used consistently. The strengthening of effects through 180 days is particularly useful. It suggests the mechanism requires sustained use consistent with 5AR inhibitions mode of action. 83.3% showed increased hair density on investigator assessment. 2020 systematic review of seven studies. Investigator assessed, not self-reported. 30-40% 5AR inhibition versus finasterides 70% and deutasterides 98%, the honest comparison that frames everything about when saw palmetto is enough 180 days, when the 2026 extension saw continued strengthening of effects, suggesting saw palmetto requires sustained use to reach full benefit, the honest comparison. Saw palmetto vs. phenasteride vs. deutasteride, the numbers side by side. Treatment 5AR inhibition prescription required deutasteride tilde 98%. Inhibits both type 1 and type 2 yes. Off label for hair in most countries. Phenasteride tilde 70%. Type 2 only, yes. FDA approved for male AGIA, off label for women, saw palmetto 32 to 38%, both type 1 and type 2, no, available OTC as supplement or topical topical Saw Palmetto follicle level inhibition without systemic DHT reduction, no, in topical hair care formulas. An important note for women. Most of the Saw Palmetto Clinical Trial data is in men. The 2020 systematic review included women, but most included studies were male predominant. The 2025 trial examined healthy men and women aged 25, 65, suggesting applicability to female androgenetic alopecia. But the evidence base is not as strong for women as for men. The mechanism, 5AR inhibition reducing DHT, is relevant regardal S of sex, since female pattern hair loss also involves androgenic sensitivity at the follicle. Important point, natural does not mean biologically inert. Any compound that significantly impacts DHT is capable of impacting androgen-sensitive tissues. At the doses in clinical trials, saw palmetto's safety profile has been consistently favorable, but it is not without biological effect, and women who are pregnant or trying to conceive should discuss any DHT modifying supplement with their doctor before using it. Who saw palmetto is enough for, and who needs more? For patients with mild androgenetic alopecia who want a non-pharmacologic treatment strategy, are unwilling to use phenasteride, or do not qualify for prescription 5 alpha reductase inhibitors, saw palmetto is a reasonable, well-tolerated choice with a two-decade evidence base. It is highly unlikely to reverse miniaturization that has already occurred and is best considered a mild adjunctive therapy or a prevention-focused intervention in early stage loss. For moderate to advanced pattern hair loss, prescription options deliver substantially better results. 30-40% 5AR inhibition is meaningfully less than 70% or 98%. At a certain stage of androgenetic hair loss, that gap matters clinically. This is not a failure of sawpalmetto. It is an honest description of what it is and isn't designed to do. Topically applied saw palmetto, as in the Laritel formula, provides follicle level DHT inhibition without the S.